Memphasys (ASX:MEM) will start in vitro utilization testing of its Felix System in China as part of an agreement with Hong Kong-based biotech company Heranova Lifesciences HK, according to a Monday filing with the Australian bourse.
Heranova will conduct testing at Sichuan Jinxin Xinan Women & Children Hospital in Chengdu to assess the usability of the system in routine and challenging in vitro fertilization cases using 50 patient cases, with the company supplying 50 Felix cartridges and one console, the filing said.
The testing will assess the biological performance and health economic benefits of the system, according to the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.